NanoString's miRGE Assay now available for use in nCounter Analysis System

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of the nCounter® miRGE Assay for use on its nCounter Analysis System. The nCounter miRGE ("merge") Assay enables researchers to investigate expression levels of both micro RNAs (miRNAs) and the messenger RNAs (mRNAs) they potentially regulate in a single reaction, without the need for amplification.

The miRGE Assay provides the capacity to perform multiplexed profiling of 5-30 miRNAs and 100-200 mRNAs simultaneously, with specificity and sensitivity comparable to qPCR. Like all nCounter assays, the kit is compatible with multiple sample types, including FFPE samples. The assay is available for human, mouse and rat samples.

"The miRGE Assay is a unique, digital assay that will enable researchers to investigate the interactions between miRNAs and their downstream mRNA targets, all in a single tube," said Barney Saunders, Chief Commercial Officer for NanoString Technologies. "miRGE delivers highly reproducible results, even for challenging samples such as FFPE tissue, making it ideal for today's translational research studies."

The nCounter Analysis System is a fully automated digital detection and counting system with a very simple workflow. The assays contain all of the reagents and consumables required to conduct an experiment. Minimal sample input requirements and compatibility with a variety of sample types, extends the utility of the platform. In addition to miRNA assays, NanoString provides assays for copy number variation and gene expression analysis. The nCounter Analysis System is currently available for Research Use Only.

Source: NanoString Technologies, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoString Technologies. (2011, September 22). NanoString's miRGE Assay now available for use in nCounter Analysis System. News-Medical. Retrieved on April 25, 2024 from https://www.news-medical.net/news/20110922/NanoStrings-miRGE-Assay-now-available-for-use-in-nCounter-Analysis-System.aspx.

  • MLA

    NanoString Technologies. "NanoString's miRGE Assay now available for use in nCounter Analysis System". News-Medical. 25 April 2024. <https://www.news-medical.net/news/20110922/NanoStrings-miRGE-Assay-now-available-for-use-in-nCounter-Analysis-System.aspx>.

  • Chicago

    NanoString Technologies. "NanoString's miRGE Assay now available for use in nCounter Analysis System". News-Medical. https://www.news-medical.net/news/20110922/NanoStrings-miRGE-Assay-now-available-for-use-in-nCounter-Analysis-System.aspx. (accessed April 25, 2024).

  • Harvard

    NanoString Technologies. 2011. NanoString's miRGE Assay now available for use in nCounter Analysis System. News-Medical, viewed 25 April 2024, https://www.news-medical.net/news/20110922/NanoStrings-miRGE-Assay-now-available-for-use-in-nCounter-Analysis-System.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay